Zurich consensus: Statement of German experts on St. Gallen Conference 2011 on Primary Breast Cancer (Zurich 2011)

Breast Care

Volumn 6, Issue 2, 2011, Pages 144-152

  Untch, Michael ^a   Gerber, Bernd ^b   Möbus, Volker ^c   Schneeweiss, Andreas ^d   Thomssen, Christoph ^e   Von Minckwitz, Gunter ^f   Beckmann, Matthias W ^g   Blohmer, Jens Uwe ^h   Costa, Serban Dan ⁱ   Diedrich, Klaus ^j   Diel, Ingo ^k   Eiermann, Wolfgang ^l   Friese, Klaus ^m   Harbeck, Nadia ⁿ   Hilfrich, Jörn ^o   Jackisch, Christian ^p   Janni, Wolfgang ^q   Jänicke, Fritz ^r   Jonat, Walter ^s   Kaufmann, Manfred ^c   Kiechle, Marion ^t   Köhler, Uwe ^u   Kreienberg, Rolf ^v   Maass, Nicolai ^w   Marschner, Norbert ^x   Nitz, Ulrike ^y   Scharl, Anton ^z   Wallwiener, Diethelm ^aa   more..

^a HELIOS KLINIKUM BERLIN BUCH   (Germany)

^b Universitatsfrauenklinik Rostock   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^f German Breast Group   (Germany)

^g UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^h MARTIN LUTHER KRANKENHAUS   (Germany)

ⁱ UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^j UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^k Gemeinschaftspraxis Gynäkologie und Geburtshilfe   (Germany)

^l Frauenklinik   (Germany)

^m LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

ⁿ UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^o Eilenriedeklinik   (Germany)

^p Klinikum Offenbach   (Germany)

^q UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^r UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^s UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^t TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^u Klinikum St Georg   (Germany)

^v UNIVERSITY HOSPITAL ULM   (Germany)

^w UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^x Gemeinschaftspraxis für Interdisziplinäre Onkologie und Hämatologie   (Germany)

^y Bethesda Monchengladbach GmbH   (Germany)

^z KLINIKUM ST MARIEN   (Germany)

^aa UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

more..

Author keywords

Early Breast Cancer; Endocrine treatment; Neoadjuvant therapy; Predictive and prognostic markers; Targeted therapy

Indexed keywords

AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CONFERENCE PAPER; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; IRRADIATION; LYMPH NODE DISSECTION; MASTECTOMY; PARTIAL MASTECTOMY; PHENOTYPE; POSTMENOPAUSE; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 79957598192     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000327999     Document Type: Conference Paper

References (10)

1. Paik S, Tang G, et al.: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. JCO 2006;24:3726-34. (Pubitemid 46622311)
2. Albain K, Barlow WE, et al.: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 2010;11:55-65.
3. Lyman GL, Giuliano AE, et al.: American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005;23:7703-20. (Pubitemid 46291835)
4. Whelan T, Pignol JP, et al.: Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010;362:513-20.
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687-717.
6. Nitz U, et al.: Superiority of sequential docetaxel over standard FE100C in patients with Intermediate risk breast cancer: Survival results of the randomized intergroup phase III trial EC-Doc. SABCS 2008; Abstr 551601.
7. Moebus V, Jackisch C, Lueck HJ et al.: Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: Mature results of an AGO phase III study. J Clin Oncol 2010;28:2874-2880.
8. Slamon D, et al.: Use of trastuzumab in the adjuvant treatment of HER2-positive breast cancer: Efficacy and safety results from the BCIRG-006 study. NEJM 2011 in press.
9. Naume B, Sorlie T: Molecular profiling of early breast cancer in relation to detection of micrometastases and outcome. Breast Cancer Research 2005;7(suppl 2):35.
10. Untch M, Fasching PA, Konecny, GE, Hasmüller S, Lebeau A, Kreienberg R et al.: Pathological complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in HER2-overexpressing breast cancer. Results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 2011, in press.